Litcius/Paper detail

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

Taiki Hakozaki, Yukio Hosomi, Akihiro Shimizu, Rui Kitadai, Kie Mirokuji, Yusuke Okuma

2020Journal of Cancer Research and Clinical Oncology32 citationsDOIOpen Access PDF

Topics & Concepts

PolypharmacyMedicineInternal medicineAdverse effectOncologyLung cancerMultivariate analysisCancer Immunotherapy and BiomarkersLung Cancer Research StudiesCancer, Stress, Anesthesia, and Immune Response
Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy | Litcius